Efficacy and safety assessment of hypertension management with coveram (Perindopril/amlodipine fixed combination) in patients with previous angiotensin receptor blocker (ARB) treatment

Arabian gulf STRONG study

Mustafa Ahmed, Muath Alanbaei, Hassan El Tamimi, Yahya Al-Wahshi, Ibrahim Al-Zakwani

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Objective: We evaluated the safety and efficacy of hypertension management with Coveram (perindopril/amlodipine combination) in patients with uncontrolled blood pressure (BP). All patients were on previous angiotensin receptor blocker (ARB) treatment. Methods: This was a 3 country, multi-centre (7 cities), open-label, observational study in the Arabian Gulf. Patients (≥ 18 years) were recruited between October 2012 and November 2013 and followed-up for 3 months after enrolment. Outcomes included changes in BP from baseline and BP goal attainment rates as per Joint National Committee-8 (<140/90 mmHg for diabetics and those <60 years of age and <150/90 mmHg for those ≥60 years of age without diabetes). Medication tolerance was also assessed from both patient and physician perspectives. Results: Hypertensive patients (n=760; mean age: 51±10 years; 67% were males) were included. A total of 178 patients (23%) were lost to follow-up. The perindopril/amlodipine combination was associated with an overall reduction in systolic BP (SBP) (31 mmHg; p<0.001) and diastolic BP (DBP) (18 mmHg; p<0.001) from baseline. An overall BP control rate was achieved in 87% (n=507) of the participants. There were significant incremental BP reductions with dose up-titration, especially SBP (p<0.001). Those with high SBP (>180 mmHg) at baseline were associated with a mean reduction of 59 mmHg (p<0.001). The perindopril/amlodipine combination had excellent tolerance levels over the study period from both patient and physician perspectives (at 99% and 98%, respectively; p<0.001). Conclusions: The perindopril/amlodipine combination is an effective and well tolerated anti-hypertensive option in patients on previous ARB treatment.

Original languageEnglish
Pages (from-to)570-575
Number of pages6
JournalCurrent Vascular Pharmacology
Volume14
Issue number6
DOIs
Publication statusPublished - Nov 1 2016

Fingerprint

Angiotensin Receptor Antagonists
Hypertension
Safety
Blood Pressure
Therapeutics
Antihypertensive Agents
Observational Studies
Viacoram
perindopril drug combination amlodipine
Physicians

Keywords

  • Angiotensin receptor antagonists
  • Angiotensin-converting enzyme inhibitors
  • Hypertension
  • Middle East
  • Perindopril amlodipine combination
  • Safety
  • Treatment effectiveness

ASJC Scopus subject areas

  • Pharmacology
  • Cardiology and Cardiovascular Medicine

Cite this

@article{3e8ef3c333514ae3894ef004ca170a0d,
title = "Efficacy and safety assessment of hypertension management with coveram (Perindopril/amlodipine fixed combination) in patients with previous angiotensin receptor blocker (ARB) treatment: Arabian gulf STRONG study",
abstract = "Objective: We evaluated the safety and efficacy of hypertension management with Coveram (perindopril/amlodipine combination) in patients with uncontrolled blood pressure (BP). All patients were on previous angiotensin receptor blocker (ARB) treatment. Methods: This was a 3 country, multi-centre (7 cities), open-label, observational study in the Arabian Gulf. Patients (≥ 18 years) were recruited between October 2012 and November 2013 and followed-up for 3 months after enrolment. Outcomes included changes in BP from baseline and BP goal attainment rates as per Joint National Committee-8 (<140/90 mmHg for diabetics and those <60 years of age and <150/90 mmHg for those ≥60 years of age without diabetes). Medication tolerance was also assessed from both patient and physician perspectives. Results: Hypertensive patients (n=760; mean age: 51±10 years; 67{\%} were males) were included. A total of 178 patients (23{\%}) were lost to follow-up. The perindopril/amlodipine combination was associated with an overall reduction in systolic BP (SBP) (31 mmHg; p<0.001) and diastolic BP (DBP) (18 mmHg; p<0.001) from baseline. An overall BP control rate was achieved in 87{\%} (n=507) of the participants. There were significant incremental BP reductions with dose up-titration, especially SBP (p<0.001). Those with high SBP (>180 mmHg) at baseline were associated with a mean reduction of 59 mmHg (p<0.001). The perindopril/amlodipine combination had excellent tolerance levels over the study period from both patient and physician perspectives (at 99{\%} and 98{\%}, respectively; p<0.001). Conclusions: The perindopril/amlodipine combination is an effective and well tolerated anti-hypertensive option in patients on previous ARB treatment.",
keywords = "Angiotensin receptor antagonists, Angiotensin-converting enzyme inhibitors, Hypertension, Middle East, Perindopril amlodipine combination, Safety, Treatment effectiveness",
author = "Mustafa Ahmed and Muath Alanbaei and {El Tamimi}, Hassan and Yahya Al-Wahshi and Ibrahim Al-Zakwani",
year = "2016",
month = "11",
day = "1",
doi = "10.2174/1570161114666160722112110",
language = "English",
volume = "14",
pages = "570--575",
journal = "Current Vascular Pharmacology",
issn = "1570-1611",
publisher = "Bentham Science Publishers B.V.",
number = "6",

}

TY - JOUR

T1 - Efficacy and safety assessment of hypertension management with coveram (Perindopril/amlodipine fixed combination) in patients with previous angiotensin receptor blocker (ARB) treatment

T2 - Arabian gulf STRONG study

AU - Ahmed, Mustafa

AU - Alanbaei, Muath

AU - El Tamimi, Hassan

AU - Al-Wahshi, Yahya

AU - Al-Zakwani, Ibrahim

PY - 2016/11/1

Y1 - 2016/11/1

N2 - Objective: We evaluated the safety and efficacy of hypertension management with Coveram (perindopril/amlodipine combination) in patients with uncontrolled blood pressure (BP). All patients were on previous angiotensin receptor blocker (ARB) treatment. Methods: This was a 3 country, multi-centre (7 cities), open-label, observational study in the Arabian Gulf. Patients (≥ 18 years) were recruited between October 2012 and November 2013 and followed-up for 3 months after enrolment. Outcomes included changes in BP from baseline and BP goal attainment rates as per Joint National Committee-8 (<140/90 mmHg for diabetics and those <60 years of age and <150/90 mmHg for those ≥60 years of age without diabetes). Medication tolerance was also assessed from both patient and physician perspectives. Results: Hypertensive patients (n=760; mean age: 51±10 years; 67% were males) were included. A total of 178 patients (23%) were lost to follow-up. The perindopril/amlodipine combination was associated with an overall reduction in systolic BP (SBP) (31 mmHg; p<0.001) and diastolic BP (DBP) (18 mmHg; p<0.001) from baseline. An overall BP control rate was achieved in 87% (n=507) of the participants. There were significant incremental BP reductions with dose up-titration, especially SBP (p<0.001). Those with high SBP (>180 mmHg) at baseline were associated with a mean reduction of 59 mmHg (p<0.001). The perindopril/amlodipine combination had excellent tolerance levels over the study period from both patient and physician perspectives (at 99% and 98%, respectively; p<0.001). Conclusions: The perindopril/amlodipine combination is an effective and well tolerated anti-hypertensive option in patients on previous ARB treatment.

AB - Objective: We evaluated the safety and efficacy of hypertension management with Coveram (perindopril/amlodipine combination) in patients with uncontrolled blood pressure (BP). All patients were on previous angiotensin receptor blocker (ARB) treatment. Methods: This was a 3 country, multi-centre (7 cities), open-label, observational study in the Arabian Gulf. Patients (≥ 18 years) were recruited between October 2012 and November 2013 and followed-up for 3 months after enrolment. Outcomes included changes in BP from baseline and BP goal attainment rates as per Joint National Committee-8 (<140/90 mmHg for diabetics and those <60 years of age and <150/90 mmHg for those ≥60 years of age without diabetes). Medication tolerance was also assessed from both patient and physician perspectives. Results: Hypertensive patients (n=760; mean age: 51±10 years; 67% were males) were included. A total of 178 patients (23%) were lost to follow-up. The perindopril/amlodipine combination was associated with an overall reduction in systolic BP (SBP) (31 mmHg; p<0.001) and diastolic BP (DBP) (18 mmHg; p<0.001) from baseline. An overall BP control rate was achieved in 87% (n=507) of the participants. There were significant incremental BP reductions with dose up-titration, especially SBP (p<0.001). Those with high SBP (>180 mmHg) at baseline were associated with a mean reduction of 59 mmHg (p<0.001). The perindopril/amlodipine combination had excellent tolerance levels over the study period from both patient and physician perspectives (at 99% and 98%, respectively; p<0.001). Conclusions: The perindopril/amlodipine combination is an effective and well tolerated anti-hypertensive option in patients on previous ARB treatment.

KW - Angiotensin receptor antagonists

KW - Angiotensin-converting enzyme inhibitors

KW - Hypertension

KW - Middle East

KW - Perindopril amlodipine combination

KW - Safety

KW - Treatment effectiveness

UR - http://www.scopus.com/inward/record.url?scp=84995624236&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84995624236&partnerID=8YFLogxK

U2 - 10.2174/1570161114666160722112110

DO - 10.2174/1570161114666160722112110

M3 - Article

VL - 14

SP - 570

EP - 575

JO - Current Vascular Pharmacology

JF - Current Vascular Pharmacology

SN - 1570-1611

IS - 6

ER -